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OBJECTIVES: The CURE trial demonstrated that clopidogrel on
top of aspirin reduces the number of cardiovascular events (CV)
compared to aspirin alone by 20% in patients with unstable
angina or non-ST-elevated myocardial infarction compared to
aspirin alone with an acceptable 1% increase of major bleedings.
Based on this result, a long-term cost-effectiveness analysis was
performed in Mexico. METHODS: An expert panel identiﬁed
the resource used by patients suffering from a stroke or an acute
MI, according to local practices. Costs were elicited from the
IMSS health care institutions. The yearly costs included the acute
and follow-up costs of events, including bleedings. Indirect costs
were calculated using the time of work lost. The effectiveness
measure was survival. The cost-effectiveness analysis used the
societal perspective and incremental cost-effectiveness ratios
(ICER) were calculated using a long-term Markov model. A 3%
discount rate was applied for costs and outcomes. Sensitivity
analysis was performed on the discount rate and the acute events’
costs. RESULTS: The model yielded greater direct costs for the
clopidogrel strategy ($12,155) vs. aspirin alone (US$11,821) and
indirect costs were $164 versus $206 respectively. Total costs in
the two arms were $12,319 for the clopidogrel strategy and
$12,027 for aspirin alone. Treatment with the clopidogrel strat-
egy resulted in a longer survival compared to aspirin (9.76 life-
year gained (LYG) vs. 9.65LYG, respectively). Therefore, the
incremental cost-effectiveness ratio of the clopidogrel strategy
was $3350/LYG for direct costs and $2938/LYG for total 
costs. The sensitivity analysis indicated a maximum ICER 
of $6570/LYG using a 5% discount rate and the lowest cost
reported per event. CONCLUSION: In this analysis, the cost per
life year gained is lower the recommended threshold of accept-
ability deﬁned by WHO (3xGDP per capita (US$30,177), indi-
cating that Clopidogrel on top of aspirin is highly cost-effective
in patients with UA/NSTEMI within the IMSS.
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OBJECTIVES: To assess the clinical effectiveness and economic
consequences of Betaloc ZOC (metoprolol succinate) or
carvedilol in treatment of cardiac insufﬁciency and hypertension
from public payer perspective in Poland. METHODS: Results of
a systematic review of published clinical trials selected in accor-
dance with EBM criteria were used to assess effectiveness and
safety of the drugs in cardiac insufﬁciency and hypertension
treatment. The economic consequences for public payer for
therapy of individual patient in case of carvedilol replacement
by Betaloc ZOC were calculated. Costs of treatment depend on
pharmacotherapy as well as risk of adverse events and proba-
bility of hospital stay due to the drugs use. Sensitivity analyses
were performed for a range of costs of Betaloc ZOC or carvedilol
generics available in Poland. RESULTS: Systematic review
revealed no “head to head” comparison between metoprolol suc-
cinate and carvedilol; indirect comparisons showed superiority
of Betaloc ZOC in cardiac insufﬁciency as well as hypertension
treatment. Annual treatment costs from public payer perspective
in case of Betaloc ZOC use were much lower than in case of
carvedilol in cardiac insufﬁciency (difference: 214.8 (51.1E)—
2696.8PLN (642E) per patient). Carvedilol was dominated by
Betaloc ZOC in hypertension treatment: Betaloc ZOC has higher
clinical effectiveness and generates savings (lower risk of adverse
events or hospitalization) compared to carvedilol: 445.17
(106E)—4270.5PLN (1016.8E) in case of annual treatment of
one patient. Sensitivity analysis showed than in most scenarios
Betaloc was cheaper from public payer perspective than
carvedilol. CONCLUSIONS: Betaloc ZOC use in place of
carvedilol lead to signiﬁcant savings for public payer in Poland
in cardiac insufﬁciency and hypertension treatment.
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OBJECTIVES: The Treating to New Targets (TNT) study, daily
treatment with atorvastatin 80 mg (A80) reduced cardiovascular
events by 22% compared with atorvastatin 10 mg (A10) in
patients with coronary heart disease (CHD). The objective of this
study was to evaluate the cost-effectiveness of this treatment
strategy in Spain and Germany. METHODS: A lifetime model
was developed to predict cardiovascular disease-related events
(resuscitated cardiac arrest, hospitalized CHF, MI, stroke, revas-
cularization, peripheral vascular disease, TIA, angina), costs, sur-
vival, and quality-adjusted life years (QALYs) for CHD patients
receiving A80 versus A10 in the target countries. Treatment-spe-
ciﬁc event probabilities were estimated from the TNT trial and
extrapolated to 10 years. Beyond year 10, equivalent cardiovas-
cular risks were assumed for all patients. Post-event survival,
event-speciﬁc utilities, and country-speciﬁc medical-care costs
were estimated using published sources. All beneﬁts and costs
(€2005) were discounted 3.5% annually. RESULTS: In both set-
tings, treatment with A80 is estimated to increase per-patient
QALYs (8.39 vs. 8.25 in Spain, 8.19 vs. 8.05 in Germany), life
years (10.99 vs. 10.86, 10.73 vs. 10.58), and costs of care
(€11,468 vs. €7883, €12,546 vs. €10,237) compared with A10.
Corresponding estimates of incremental cost-effectiveness of
A80 versus A10 in each setting are €27,445 and €16,566 per
QALY, and €26,912 and €15,809 per life year saved (LYS). In
probabilistic sensitivity analysis, the likelihood that A80 is cost-
effective versus A10 (<€30,000/QALY or LYS) is 59.1% and
91.3% for QALY, and 60.3% and 88.0% for LYS, respectively.
CONCLUSIONS: Intensive A80 treatment is estimated to be
cost-effective versus A10 in secondary cardiovascular prevention
in Spain and Germany. While prior studies have demonstrated
the cost-effectiveness of moderate lipid-lowering therapy versus
no treatment in this patient population, the results of our analy-
sis suggest more intensive lipid lowering with atorvastatin also
can be justiﬁed on cost-effectiveness grounds versus moderate
statin therapy.
